Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.

Summary

To evaluate the safety and efficacy of anti-PD-1 (toripalimab) combined with cisplatin concurrent IMRT for locally advanced cervical cancer.

Timeline

Start

2020-05-08

Primary completion

2021-12-31

Completion

2022-12-31

Publications

• Jiang P, Wei S, Li C, Qu A, Chen H, Zhang H, Guo H, Wang J. Safety and efficacy of toripalimab plus concurrent chemoradiotherapy for locally advanced cervical cancer: a single-arm, phase Ib trial. BMC Cancer. 2025 Oct 14;25(1):1566. doi: 10.1186/s12885-025-15059-y.

Drugs

Indications